Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll Biopharma Appoints David Hernandez as Vice President of Clinical Development Operations


Related Data

HanAll Biopharma today announced the appointment of David Hernandez as Vice President of Clinical Development Operations. Hernandez previously served as Head of Clinical Operations Japan at Merck Biopharma Co., Ltd./Merck KGaA.

Hernandez will focus on leading operations of HanAll’s clinical trials and report to Sean Jeong, M.D., Co-CEO of HanAll Biopharma and CEO of HanAll Pharmaceutical International (HPI), working at HPI, a U.S. entity wholly owned by HanAll Biopharma.  

Hernandez has 22 years of experience in clinical operations in both academic environments and in pharmaceutical companies, with background in various therapeutic areas including CNS, Oncology, Immunology, and Type 2 Diabetes.

“David is an expert in trial management who has successfully executed complex projects in all development phases at various multinational pharmaceutical companies, ranging from a start-up company to very large companies,” said Sean Jeong. “Ongoing projects including HL036 and HL161 in the US and Japan as well as a further pipeline through open innovation in the future will be strengthened through his expertise.

“I’m excited to join the team at HanAll.  The pipeline products have great promise and potential to help many patients in areas of unmet need, and I’m impressed with the company’s leadership to bring these products to market with great urgency.  HanAll’s vision and commitment to patients are inspirational and I can’t wait to contribute to the realization of this vision,“ said Hernandez of his appointment.